The Cardiopulmonary Effects of the Calcitonin Gene-related Peptide Family

Area of Science:

• Cardiology
• Pulmonology
• Endocrinology

Background:

• Cardiopulmonary diseases represent a significant global health burden with high treatment costs.
• Current treatment options for these conditions remain limited, necessitating the exploration of novel therapeutic avenues.
• The calcitonin-gene related-peptide (CGRP) family has been investigated for its potential therapeutic roles in cardiopulmonary medicine.

Purpose of the Study:

• To review the current understanding of CGRP family members' roles in cardiopulmonary diseases.
• To highlight adrenomedullin and adrenomedullin2/intermedin as promising therapeutic targets.
• To consolidate existing research on CGRP family peptides in cardiopulmonary disease treatment.

Main Methods:

• Literature review of studies investigating CGRP family members.
• Analysis of research focusing on adrenomedullin and adrenomedullin2/intermedin.
• Synthesis of findings related to cardiopulmonary disease mechanisms and CGRP signaling.

Main Results:

• CGRP family members exhibit diverse functions relevant to cardiopulmonary health.
• Adrenomedullin and adrenomedullin2/intermedin demonstrate significant potential in preclinical and clinical studies.
• Evidence suggests these peptides can modulate key pathways implicated in cardiopulmonary pathologies.

Conclusions:

• CGRP family members, particularly adrenomedullin and adrenomedullin2/intermedin, offer a promising therapeutic frontier for cardiopulmonary diseases.
• Further research into the mechanisms and clinical applications of these peptides is warranted.
• Targeting the CGRP pathway could lead to innovative treatments for prevalent cardiopulmonary conditions.